The complex ST2L/IL-33 has a cardioprotective effect, limiting cardiomyocyte apoptosis, fibrosis and cardiac hypertrophy, whereas sST2 acts as a decoy receptor for IL-33, preventing its beneficial effects and leading to cardiac fibrosis, ventricular remodeling and negative cardiac outcomes [113]. The gene discussed is IL33; the disease is cardiac hypertrophy.